These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 27699860)
41. An answer to some questions raised by skin reactions observed during squaric acid dibutylester contact sensitization. Happle R Contact Dermatitis; 2001 Sep; 45(3):189-90. PubMed ID: 11553162 [No Abstract] [Full Text] [Related]
42. Epidermodysplasia verruciformis: successful treatment with squaric acid dibutylester. Kehdy J; Erickson C; Rady P; Tyring S; Gaspari AA Cutis; 2015 Aug; 96(2):114-8. PubMed ID: 26367749 [TBL] [Abstract][Full Text] [Related]
43. Side-effects during treatment with SADBE. Frattasio A; Germino M; Cargnello S; Patrone P Contact Dermatitis; 1997 Feb; 36(2):118-9. PubMed ID: 9062760 [No Abstract] [Full Text] [Related]
44. Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata. Kagami S; Kishi Y; Hino H J Cosmet Dermatol; 2020 Sep; 19(9):2411-2414. PubMed ID: 32621407 [TBL] [Abstract][Full Text] [Related]
45. Topical immunotherapy of alopecia areata. A follow-up study. Valsecchi R; Cainelli T; Foiadelli L; Rossi A Acta Derm Venereol; 1986; 66(3):269-72. PubMed ID: 2426909 [TBL] [Abstract][Full Text] [Related]
46. [Controlled study of the efficacy of topical immunotherapy in alopecia areata: squaric acid versus placebo]. Pigatto PD; Rapisarda R; Polenghi MM; Altomare GF G Ital Dermatol Venereol; 1987 Dec; 122(12):667-70. PubMed ID: 3329149 [No Abstract] [Full Text] [Related]
47. Determination of in vivo dose response and allergen-specific T cells in subjects contact-sensitized to squaric acid dibutyl ester. Camouse MM; Swick AR; Ryan CA; Hulette B; Gerberick F; Tinkle SS; Nedorost ST; Cooper KD; Stevens SR; Baron ED Dermatitis; 2008; 19(2):95-9. PubMed ID: 18413111 [TBL] [Abstract][Full Text] [Related]
48. Fexofenadine hydrochloride enhances the efficacy of contact immunotherapy for extensive alopecia areata: Retrospective analysis of 121 cases. Inui S; Nakajima T; Toda N; Itami S J Dermatol; 2009 Jun; 36(6):323-7. PubMed ID: 19500180 [TBL] [Abstract][Full Text] [Related]
49. Photochemotherapy plus squaric acid dibutylester in alopecia areata treatment. Orecchia G; Perfetti L; Borroni G; Rabbiosi G Dermatologica; 1990; 181(2):167-9. PubMed ID: 2242789 [No Abstract] [Full Text] [Related]
50. Lentiginous eruption due to topical immunotherapy. Tosti A; Piraccini BM; Misciali C; Vincenzi C Arch Dermatol; 2003 Apr; 139(4):544-5. PubMed ID: 12707112 [No Abstract] [Full Text] [Related]
51. [In situ lymphocyte subpopulation in alopecia areata after treatment with squaric acid dibutyl ester]. Rosso R; Paulli M; Marelli MA; Douville H; Orecchia G G Ital Dermatol Venereol; 1988 Nov; 123(11):575-7. PubMed ID: 3254332 [No Abstract] [Full Text] [Related]
52. [DNCB therapy of alopecia areata]. Happle R Z Hautkr; 1979 May; 54(10):426-9. PubMed ID: 314203 [TBL] [Abstract][Full Text] [Related]
53. Topical immunotherapy for alopecia areata: re-evaluation of 139 cases after an additional follow-up period of 19 months. van der Steen PH; Boezeman JB; Happle R Dermatology; 1992; 184(3):198-201. PubMed ID: 1392112 [TBL] [Abstract][Full Text] [Related]